Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Lung Cancer considered is funded in part by AstraZeneca, Bristol Myers Squibb, Lilly Oncology, and Merck KGaA.
Podcast hosts
No host has claimed this podcast yet, if you are the host you can verify ownership by claiming this podcast
© All rights reserved
Lung Cancer Considered
Read more
Reviews
TBobo
5 out of 5 stars
Episode on Immunotherapy
Really enjoyed the conversation between these oncologist. They seem to be great doctors who really care for their patients are working for the best solutions they know of. It was also interesting to see their blind spots. The great thing about immunotherapy is slowly opening the door between integrative oncology and traditional oncology. These guys don’t get into it but they are asking the right questions. 1) What can be combined with immunotherapy? 2) What can be done to prevent side effects of traditional treatment? 3) What things can be done to both enhance traditional treatments and lower side effects? Naturopath and integrative doctors know many possible answer to these questions based on case studies and their personal experience. Things that will never get a $500 million dollar set of clinical trials, but have worked for patient after patient. - Infrared Saunas to detox from chemo and have much fewer side effects (combined with other detox techniques). - High Dose Melatonin to reduce radiation damage - with early limited clinical trials as evidence. - Hypothermia for combining with immunotherapy. - Proton radiation on a different schedule than normal to promote immunotherapy (3 day on 4 day off cycle seems to work better than the traditional 5 day on 2 day off, to give the immune system a chance to do its thing). - Micro-biome research to enhance immunotherapy both through diet, supplements, and even fecal transplants. - Natural products and off-label drugs to help limit the metabolism of cancer to slow down its growth, keep it from mutating to new food sources, and ultimately make chemo and other treatments more effective, as well as providing a much greater quality of life for the patients. If transitional oncology would do two things, immunotherapy will advance much faster. 1) Eat a bite of humble pie and realize integrative doctors and oncologist have some answers, and start having conversations with them. 2) Realize their training and education failed them in the areas of nutrition, health, and epi-genetics. 3) Realize the level of corruption in the FDA, NIH, and pharmaceutical companies, with at least 350 MILLION dollars being passed under the table to individual for the last 10 years. This seems to be greatly hampering the rules being used to approve new drugs - creating measure that have nothing to do with patient survival - but do help big pharma profits. So after realizing there is this level of corruption and unethical behavior, it is illogical and unethical to continue to just rely on these groups to produce the “cures” for cancer. It is going to take people doing and trying things have have more ethical motivations, writing papers, doing smaller trials, and forcing innovation solutions down the throat of the FDA with them kicking an screaming. Then someone needs to do something to STOP the unethical price gouging of the Pharma on immunotherapy. The are obviously coordinating their pricing in a cornered market. Again unethical and unjustified. We need to vote for political leaders who can pass some laws to bring this into account. And all the Cancer patient advocacy groups that are SILENT on these issues need to be shamed into action… even though they get big donations from big Pharma too.
DrFLC
5 out of 5 stars
Fantastic for doctors, nurses, patients
Great conversations on all things lung cancer.
yeoohaz
5 out of 5 stars
:)
great info!
Podcast information
- Amount of episodes
- 155
- Subscribers
- 0
- Verified
- No
- Website
- Explicit content
- No
- Episode type
- episodic
- Podcast link
- https://podvine.com/link/..
- Last upload date
- March 24, 2023
- Last fetch date
- March 28, 2023 2:20 AM
- Upload range
- WEEKLY
- Author
- IASLC
- Copyright
- All rights reserved
susbcribers
- IASLC - SCLC 2023 Meeting PreviewIn this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a conversation about small cell lung cancer and previews the upcoming IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer in April which is focused on both preclinical and clinical advances in small cell lung cancer research. Joining the conversation are Dr. Alvaro Quintanal-Villalonga from the Rudin Lab at Memorial Sloan Kettering Cancer Center in New York, and Dr. Kate Sutherland from the Walter and Eliza Hall Institute of Medical Research in Australia.0 comments0
- IASLC The Great Debate Dr. Einhorn Dr. Simone And Dr. FloresIn this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation about the use of consolidated radiation in early-stage small cell lung cancer. Joining the debate are Dr. Lawrence Einhorn from the Indiana University School of Medicine and Dr. Charles Simone from Memorial Sloan Kettering.0 comments0
- Lung Cancer Considered Mar 9 · 38m LCC Targeted Therapy RecapIn this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a recap of the recent IASLC meeting, Targeted Therapies for Lung Cancer, or TTLC23 --a member-favorite, a relatively smaller meeting known for its fast pace and its breadth of content. Guests include, the two co-chairs of the meeting: Dr. Charu Aggarwal, thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania. Dr. Joel Neal, thoracic medical oncologist and Associate Professor at Stanford University where he is also the Medical Director for the Cancer Clinical Trials Office.0 comments0
- IASLC - NeoadjuvantIn this Virtual Tumor Board episode of Lung Cancer Considered, host Dr. Stephen Liu and his guests discuss the dynamic topic of managing resectable stage III NSCLC. Joining him are: Dr. Isabelle Schmitt-Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung Cancer. Dr. Jonathan Spicer, Medical Director of the Thoracic Oncology Program at McGill University in Montreal where he is the Advanced Thoracic and Upper GI Surgical Oncology Fellowship Program Director. He is also a co-author of the CheckMate 816 study. Dr. Tina Cascone, Assistant Professor and Thoracic Medical Oncologist at the University of Texas MD Anderson Cancer Center and Principal Investigator of the neoadjuvant NEOSTAR study.0 comments0
- IASLC EGFR AM And PMIn this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a specific subset of lung cancer: EGFR exon 20 insertion NSCLC. Joining the podcast are distinguished panel of clinicians and lung cancer advocates: Dr. Rosario Garcia Campelo, the Head of Medical Oncology and the Thoracic Tumor Unit Chair at the University Hospital A Coruna, Spain. Marcia Horn, executive director of the Exon 20 Group and CEO of ICAN, the International Cancer Advocacy Network. Yonsei University College of Medicine, Professor Byoung-Chul Cho, Director of the Lung Cancer Center at Yonsei Cancer Hospital in Seoul, South Korea.0 comments0
- IASLC RET NSCLCIn this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pipeline. Podcast guests are: Dr. Justin Gainor, the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. His major research interests have focused on targeted therapy and immunotherapy. Dr. Lizza Hendricks, Assistant Professor at research institute GROW, School for Oncology and Developmental Biology of Maastricht University in the Netherlands. Her focus area is thoracic oncology, in particular prevention and optimal treatment of brain metastases in lung cancer and targeted therapy. Since 2019, Dr Hendriks has coordinated the clinical lung cancer research of the lung diseases department in Maastricht.0 comments0
- IASLC - KRAS G12CIn this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a conversation on KRAS G12C mutation. Joining the podcast are Dr. Melissa Johnson, the Program Director of Lung Cancer Research at the Sarah Cannon Research Institute and Dr. Ferdinandos Skoulidis, an Associate Professor at the University of Texas MD Anderson Cancer Center.0 comments0
- IASLC - LALCA HighlightsThe Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January. To provide a summary of key findings from the meeting, Lung Cancer Considered host Dr. Narjust Florez interviewed two prominent oncologists from South America: Dr. Clarissa Mathias, Dr. Mathias is a medical oncologist and director of NOB/Oncoclinicas in Brazil. She is a member of the ASCO International Quality Steering Group and Lung cancer committee. Dr. Mathias served on the IASLC board and has led many efforts in thoracic oncology in Brazil and recently hosted an episode of Lung Cancer Considered in Portuguese. Dr. Carlos Barrios, born in Uruguay but practicing oncologist in Brazil. Dr. Barrios is Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine.0 comments0
- Lung Cancer Considered Feb 2 · 30m IASLC FDA Approval Adjuvant Pembrolizumab For NSCLCOn January 26, 2023, the US FDA granted approval of pembrolizumab, an anti-PD-1 antibody, as an adjuvant therapy for patients with resected NSCLC. In this episode of Lung Cancer Considered host Dr. Stephen Liu leads a discussion on this approval with two thoracic medical oncologists with extensive expertise in this space: Dr. Jamie Chaft, an Associate Attending at Memorial Sloan Kettering Cancer Center, where she is the Director of Early Stage Lung Cancer Research, chair of the adjuvant nivolumab trial within the ALCHEMIST program and heavily involved in perioperative systemic therapy studies. Dr. Mary O’Brien, Professor and Consultant Medical Oncologist at the Royal Marsden in Surrey, Head of the Lung Unit, and chair of the EORTC Lung Cancer Group. She was one of the investigators on the KEYNOTE 091 trial which provided key data that lead to this approval.0 comments0
- IASLC IPASS Study 2In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.0 comments0
- Lung Cancer In Brazil with Clarissa Maria Cerqueira, Mathias Ticiana Leal And Carlos G. FerreiraIn a special episode of Lung Cancer Considered focusing on lung cancer in Brazil, host Dr. Clarissa Mathias, medical oncologist at Oncoclinicas Bahia and Hospital Santa Izabel, is joined by Dr. Ticiana Leal, associate professor, Department of Hematology & Oncology and director of Thoracic Medical Oncology, Winship Cancer Institute, Emory University and Dr. Carlos Gil Ferreira, president of Instituto Oncoclinicas and chief medical officer – Oncoclínicas.0 comments0
- Patient Advocacy Groups with Janet Freeman-Daily, Seamus Cotter & Terri ConneranHost Dr. Narjust Florez engages with three leading lung cancer patient advocates on the importance of patient advocacy groups, how these were formed, challenges when managing large patient advocacy groups and the future of patient advocacy in lung cancer. Janet Freeman-Daily is a cancer patient research advocate and activist who translates the experience and science of cancer for others. She was diagnosed with advanced lung cancer in 2011 and metastatic ROS1+ lung cancer in 2012. She collaborates, writes, and speaks with cancer organizations both internationally and within the USA, and blogs at Gray Connections. Seamus Cotter is from Ireland and was diagnosed with stage IV NSCLC lung cancer in June 2016 and has shared his experiences with immunotherapy on many global platforms. Since his diagnosis, Seamus has been involved in drug development and the improvement of clinical trials in lung cancer. He is deeply involved in the Irish Lung Cancer Community and is also a Patient Consultant on the lung group in Cancer Trials Ireland. Terri Conneran is one of the founders of the non-profit group “KRAS Kickers.” She was diagnosed with stage IIIa KRAS + lung cancer and has experienced separate recurrences and has persevered through multiple treatments and has dedicated her time to patient advocacy. Terri has shared her story on national and international platforms and created a community beyond lung cancer for all patients with KRAS-driven cancers.0 comments0
- Radon with Hina Khan And Laura MezquitaRadon exposure is a known risk factor for lung cancer yet it does not garner as much attention as other risk factors. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses radon, its impact on lung cancer diagnosis, new research covering radon and strategies to improve our patients and the general population's exposure to this radioactive gas. Her guest is Dr. Hina Khan, thoracic medical oncologist at the Lifespan Cancer Center and an assistant professor at The Warren Alpert Medical School of Brown University. Dr. Khan has studied the effect of radon in lung cancer and its genomic profile.0 comments0
- Radiology - Management of Lung Cancer with Florian Fintelmann and Carole RidgeRadiologists play central roles in the detection of lung cancer, in assessing response to therapy and relapse of disease and increasingly, interventional radiologists are involved with tissue sampling and lung cancer treatment. In this episode of Lung Cancer Considered, host Dr. Stephen Liu interviews two noted radiologists--Dr. Carole Ridge and Dr. Florian Fintelmann. Dr. Ridge is a consultant radiologist at Royal Brompton Hospital and a Senior Clinical Research Fellow at Imperial College London. Her research was awarded the Royal Academy of Medicine in Ireland medal in 2018. Dr. Florian Fintelmann is an Associate Professor at Harvard Medical School and a thoracic radiologist at Massachusetts General Hospital. He also leads the Thoracic Imaging Percutaneous Thermal Ablation program at the MGH.0 comments0
- Lung Cancer Considered Dec 16 · 30m FDA Approval: Adagrasib with Sheena Bhalla and Joshua SabariThis week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla (@SheenaBhallaMD), assistant professor of Medicine and Thoracic Oncologist at UT Southwestern Medical Center in Dallas.0 comments0
- Lung Cancer in Israel with Alona Zer, Jair Bar and Nir PeledIn this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in Israel, spoken in Hebrew. Host Dr. Alona Zer, Head of the Department of Medical Oncology at the Rambam Health Care Campus, Haifa, Israel welcomes guests Dr. Jair Bar, Deputy Director, Institute of Oncology at Chaim Sheba Medical Center and Associate Professor of Oncology, School of Medicine at Tel Aviv University and Dr. Nir Peled, Head, the Cancer Institute at Shaare Zedek Medical Center and Full Professor, Internal Medicine & Medical Oncology, Faculty of Health Sciences at Ben-Gurion University of the Negev, Beer Sheva, Israel.0 comments0
- ACLC & ESMO Asia 2022 HighlightsIn this episode of Lung Cancer Considered, host Dr. Stephen Liu and invited guests to discuss the IASLC Asian Conference on Lung Cancer (ACLC) held in Japan and the ESMO Asia meeting held in Singapore. Guests include Dr. James Yang, director and Professor of the Graduate Institute of Oncology at the National Taiwan University and the director of the Department of Oncology at the National Taiwan University Hospital, Dr. Thanyanan Baisamut, consultant in the Division of Medical Oncology at Ramathibodi Hospital and Mahidol University in Thailand, and Dr. Takashi Setothor, thoracic medical oncologist from the National Kyushu Cancer Center in Fukuoka, Japan.0 comments0
- Lung Cancer in the Middle East with Nagla Karim, Houssein Abdul Sater, and Abdelrahman MohamedIn this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in the Middle East (North Africa), spoken in Arabic. Host Dr. Nagla Karim, MD, PHD, Director of the Phase I Program at the Inova Schar Cancer Institute welcomes guests Dr. Abdelrahman Mohamed, MD, Head of Thoracic Surgery, NCI at Cairo University and Dr. Houssein Abdul Sater, MD, Physician Scientist, Immuno-Oncology and Regional Research Director, Cancer Institute at Cleveland Clinic Florida.0 comments0
- MET In NSCLC with Noemi Reguart and Ross CamidgeThis episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.0 comments0
- EMPOWER-Lung 3 with Jordi Remon and Isabel PreeshagulThis episode of Lung Cancer Considered is part of our series on FDA approvals of new lung cancer therapies. Today, host Dr. Stephen Liu discusses the EMPOWER-Lung 3 regimen of the PD-1 inhibitor cemiplimab with first-line platinum doublet chemotherapy for advanced NSCLC. This regimen was approved by the FDA on November 8, 2022. His guests are Dr. Jordi Remon, a thoracic medical oncologist who had previously practiced at Hospital de Mataro in Barcelona. He is now part of the esteemed thoracic unit at Gustave Roussy in Paris and the secretary of the Lung Cancer Group of EORTC. Joining Dr. Remon is Dr. Isabel Preeshagul, a thoracic medical oncologist and Assistant Attending with Memorial Sloan Kettering. She is also the chair of the Education and Engagement Committee of the Lung Cancer Research Foundation.0 comments0
- Lung Cancer Considered Nov 28 · 33m The POSEIDON Trial With Tejas PatilDr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC).0 comments0
- Evolution Of Stage III NSCLC with Martin Reck and Paula Antonia Ugalde FigueroaIn this episode of Lung Cancer Considered, host Dr. Stephen Liu, Director of Thoracic Oncology at Georgetown University, leads a discussion about the management of stage III NSCLC. Joining him are pulmonologist Dr. Martin Reck, Head of the Department of Thoracic Oncology and the Head of the Clinical Trials Department at the Lung Clinic Grosshansdorf and thoracic surgeon Dr. Paula Antonia Ugalde Figueroa, an Associate Surgeon in the Division of Thoracic Surgery at Brigham and Women’s Hospital in Boston, MA. Dr. Reck has led many of the oncology trials that have defined the standard of care for lung cancer including KEYNOTE-024 and more recent efforts in stage III NSCLC like KEYNOTE-799. Dr. Ugalde has been a pioneer in minimally invasive surgery from her time as director of Thoracic Oncology research at Laval University in Quebec to her current position at the Dana Farber Cancer Institute. She is currently a member of the Board of Directors of IASLC.0 comments0
- Climate Change & Lung Cancer, Part 2 with Christine Berg And Roselle De GuzmanThere has been a steady stream of research presented that ties air pollution to an increased risk for lung cancer. To discuss this trend, Lung Cancer Considered host Dr. Narjust Florez interviews Dr. Roselle De Guzman, who is a medical oncologist and professor at the Manila Central University in the Philippines and the Chair of ASCO Asia Pacific Regional Council. Joining her is Dr. Christine D. Berg, former Chief, Early Detection Research Group, Division of Cancer Prevention, at the National Cancer Institute.0 comments0
- Seminal Trial Series: ECOG 1594At the time it was published in the New England Journal of Medicine in 2002, ECOG 1594 was the first study to compare whether any of the three chemotherapy regimens used at the time was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez interview the ECOG 1594 clinical trial investigators (Dr. Frances Shepherd, Dr. Alan Sandler, Dr. Chandra Belani, Dr. Corey Langer and Dr. Joan Schiller) to learn just how important, and controversial, this study was.0 comments0
- Lung Cancer Care In Rural US With Debora Bruno And Gabrielle RocqueLung cancer research is often centered at large, urban academic medical centers. But what research and treatment options are available for those patients with lung cancer who live in rural areas? In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses the state of rural lung cancer care and research with Dr. Debora Bruno, a thoracic medical oncologist at Case Western in Cleveland. Dr. Bruno worked in rural Nebraska for three years after the completion of her fellowship where she was able to help establish a multi-disciplinary clinic for patients with lung cancer. Also participating in the podcast is Dr. Gabrielle Rocque, associate professor of medicine at the O’Neal Comprehensive Cancer Center at the University of Alabama. Dr. Rocque has a strong interest in the interface between community oncology practices and academia.0 comments0
Podcast hosts
No host has claimed this podcast yet, if you are the host you can verify ownership by claiming this podcast
© All rights reserved
![astro[sound]bites](https://podvine.com/cdn-cgi/image/width=250/https://images.podvine.com/162475f7c56e7c4efaa0e0f78f67681546b10c2f.jpeg "astro[sound]bites")
